Karo Pharma AB (KARO):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10031)
◆英語タイトル:Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10031
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:53
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Karo Pharma AB (Karo Pharma), formerly Karo Bio AB, is a health care company that focuses on research and development of pharmaceutical products in the areas of cancer and autoimmune diseases. Its key research area involves nuclear receptors as target proteins for the development of new pharmaceuticals. Karo Pharma discovers drugs to target major diseases including autoimmune diseases such as multiple sclerosis; and multiple types of cancer, viral and bacterial infections. The company’s projects are based on ROR gamma receptor and estrogen receptor. Its development pipeline also includes T268A Cold Spray which utilizes glucose oxidase enzyme in combination with glucose to fight against cold virus. Karo Pharma is headquartered in Huddinge, Stockholm, Sweden.

Karo Pharma AB (KARO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karo Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Karo Pharma AB, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 12
Private Equity 14
EQT VIII to Acquire Karo Pharma for USD652.6 Million 14
Partnerships 15
Karo Bio Enters Into Research Agreement With 4D Science 15
Licensing Agreements 16
Karo Pharma Enters into Licensing Agreement with Marinomed Biotech 16
Weifa Enters into Licensing Agreement with AFT Pharma 17
Karo Bio Enters into Licensing Agreement with Pelago Bioscience for CETSA 18
Equity Offering 19
Karo Pharma Raises USD151.5 Million in Rights Offering of Shares 19
Karo Bio to Raise USD29.7 Million in Rights Offering of Preferred Shares 20
Weifa Raises USD13.6 Million in Private Placement of Shares 21
Karo Bio Raises USD29 Million in Rights Offering of Shares 22
Aqualis to Raise USD116.7 Million in Private Placement of Shares 23
Aqualis to Raise USD16.7 Million in Rights Offering of Shares 24
Karo Bio Raises USD12 Million in Rights Offering of Shares 25
Karo Bio Raises USD1 Million in Private Placement of Shares 26
Aqualis Completes Private Placement Of Shares For US$4 Million 27
Aqualis Completes Private Placement Of Shares For US$4.7 Million 28
Aqualis Completes Rights Offering Of Shares For US$9 Million 29
Karo Bio Completes Rights Offering of Shares for USD4.9 Million 30
Debt Offering 31
Aqualis to Raise USD66.7 Million in Public Offering of Bonds 31
Asset Transactions 32
Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 32
Acquisition 33
Karo Pharma Acquires Weifa 33
Karo Pharma Acquires 100% Stake in Medireduce 35
Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 36
Karo Bio Acquires Tanomed for USD2.3 Million 37
Aqualis Completes Acquisition of Weifa for USD183.6 Million 38
Karo Pharma AB – Key Competitors 39
Karo Pharma AB – Key Employees 40
Karo Pharma AB – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Jul 19, 2018: Karo pharma triples sales and profit in the second quarter 42
Apr 26, 2018: Karo Pharma Doubles Sales and Earnings in the First Quarter 44
Feb 22, 2018: Karo Pharma: Year-end Report 2017 45
Nov 02, 2017: Karo Pharma: Interim Report January– September 2017 46
Aug 24, 2017: Karo Pharma: Interim Report January–June 2017 48
May 10, 2017: Karo Pharma: interim report January – March-2017 49
Feb 28, 2017: Karo Pharma: Full Year Report 2016 50
Corporate Communications 51
Mar 23, 2018: Karo Pharma Supports Operation Smile 51
Product News 52
05/21/2018: UTILITY Therapeutics Receives Qualified Infectious Disease Product Designation from the U.S. FDA for Mecillinam 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Karo Pharma AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karo Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karo Pharma AB, Deals By Therapy Area, 2012 to YTD 2018 9
Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 12
EQT VIII to Acquire Karo Pharma for USD652.6 Million 14
Karo Bio Enters Into Research Agreement With 4D Science 15
Karo Pharma Enters into Licensing Agreement with Marinomed Biotech 16
Weifa Enters into Licensing Agreement with AFT Pharma 17
Karo Bio Enters into Licensing Agreement with Pelago Bioscience for CETSA 18
Karo Pharma Raises USD151.5 Million in Rights Offering of Shares 19
Karo Bio to Raise USD29.7 Million in Rights Offering of Preferred Shares 20
Weifa Raises USD13.6 Million in Private Placement of Shares 21
Karo Bio Raises USD29 Million in Rights Offering of Shares 22
Aqualis to Raise USD116.7 Million in Private Placement of Shares 23
Aqualis to Raise USD16.7 Million in Rights Offering of Shares 24
Karo Bio Raises USD12 Million in Rights Offering of Shares 25
Karo Bio Raises USD1 Million in Private Placement of Shares 26
Aqualis Completes Private Placement Of Shares For US$4 Million 27
Aqualis Completes Private Placement Of Shares For US$4.7 Million 28
Aqualis Completes Rights Offering Of Shares For US$9 Million 29
Karo Bio Completes Rights Offering of Shares for USD4.9 Million 30
Aqualis to Raise USD66.7 Million in Public Offering of Bonds 31
Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 32
Karo Pharma Acquires Weifa 33
Karo Pharma Acquires 100% Stake in Medireduce 35
Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 36
Karo Bio Acquires Tanomed for USD2.3 Million 37
Aqualis Completes Acquisition of Weifa for USD183.6 Million 38
Karo Pharma AB, Key Competitors 39
Karo Pharma AB, Key Employees 40
Karo Pharma AB, Subsidiaries 41

List of Figures
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Karo Pharma AB (KARO):製薬・医療:M&Aディール及び事業提携情報(Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆